However, targeting TR1 for melanoma treatment alone is unlikely to lead to any therapeutic outcomes due to the ability of compensatory antioxidant mechanisms to be engaged via NRF2 activation [43,137]. The gene discussed is TXNRD1; the disease is melanoma.